Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cincinnati
With
AstraZeneca
This research study is designed to see if the study drug, durvalumab, will work better with cetuximab than either medicine alone along with the evaluation of side effects of the drug combination.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body weight \> 30 kg
Histologically or cytologically confirmed recurrent or metastatic HNSCC
Not considered a candidate for other curative therapy (i.e. surgery/RT)
Documented progression of disease after receiving platinum based regimen
ECOG performance status 0-2
You may not be if
Nasopharyngeal and salivary gland tumors
Prior exposure to both immunotherapy drugs and Cetuximab. Single exposure to either immunotherapy or cetuximab is allowed.
Clareo Health | Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
